ERBB2 and neoplasm: Intravenous delivery (via tail vein) of HSi in mice bearing human xenografts of HER3+ tumors significantly reduced tumor growth rates (Figure 8C), corresponding to a substantial reduction of ErbB2 (Figure 8D).